60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
0.450
-0.023 (-4.88%)
At close: Feb 21, 2025, 4:00 PM
0.440
-0.010 (-2.22%)
After-hours: Feb 21, 2025, 7:48 PM EST
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $148.11K in the quarter ending September 30, 2024, with 16.85% growth. This brings the company's revenue in the last twelve months to $462.61K, up 128.99% year-over-year. In the year 2023, 60 Degrees Pharmaceuticals had annual revenue of $253.57K, down -50.40%.
Revenue (ttm)
$462.61K
Revenue Growth
+128.99%
P/S Ratio
1.17
Revenue / Employee
$154,204
Employees
3
Market Cap
3.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
Dec 31, 2020 | 2.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSXTP News
- 1 day ago - 60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 2 days ago - 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - GlobeNewsWire
- 11 days ago - Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® - GlobeNewsWire
- 15 days ago - 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 17 days ago - 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 22 days ago - 60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 25 days ago - 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire
- 6 weeks ago - 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis - GlobeNewsWire